Bio-Techne

138 articles with Bio-Techne

• Bio-Techne Signs Strategic Cooperation Agreement with Micropoint Bioscience

  10/12/2018

  Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China.

• Bio-Techne Scientist Presented with the CASSS CE Pharm Award

  10/2/2018

  Bio-Techne is proud to announce that one of its Principal Scientists, Jiaqi Wu, Ph.D., was presented with the CE Pharm Award at this year's CE Pharm meeting, September 9-12, 2018, for his contributions to the capillary electrophoresis (CE) field.

• Bio-Techne Announces Cell and Gene Therapy Initiative

  9/27/2018

  Bio-Techne has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing.

• Bio-Techne Announces Publication of Data Demonstrating Additional Clinical Validation of its EPI Test in European Urology Journal

  9/18/2018

  Bio-Techne today announced the online publication of its second prospective US clinical validation study of the Exosome Diagnostics-branded ExoDx® Prostate(IntelliScore) (EPI)

• Bio-Techne Fills a Need for Simple Tools to Study Glycobiology

  9/6/2018

  Bio-Techne researchers publish papers that promise to open the field of glycobiology to the masses.

• Bio-Techne To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

  9/5/2018

  Bio-Techne Corporation today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018, at 8:00 a.m. EDT.

• Bio-Techne To Present At The Baird 2018 Global Healthcare Conference

  8/28/2018

  Bio-Techne Corporation today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Baird 2018 Global Healthcare Conference on Thursday, September 6, 2018, at 9:40 a.m. EDT.

• Bio-Techne Introduces GMP Small Molecules for Stem Cell Therapy Development

  8/8/2018

  Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for use as ancillary materials in the development of stem cell therapies.

• Bio-Techne Releases Fourth Quarter Fiscal 2018 Results

  8/7/2018

  Bio-Techne Corporation reported its financial results for the fourth quarter ended June 30, 2018.

• Bio-Techne Declares Dividend Payable August 31, 2018

  8/7/2018

  Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2018.

• Bio-Techne Corporation Completed Its Acquisition of Exosome Diagnostics, Inc.

  8/1/2018

  Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Exosome Diagnostics, Inc.

• Bio-Techne Introduces New Member of the Simple Western™ Family, with IR/NIR Detection Capabilities

  7/24/2018

  Bio-Techne again disrupts protein analysis technology with the introduction of the newest member of their ProteinSimple-branded Simple Western family, Jess.

• Bio-Techne To Host Conference Call On August 7, 2018 To Announce Fourth Quarter 2018 Financial Results

  7/12/2018

  Bio-Techne Corporation announced that management will host a conference call on Tuesday, August 7, 2018 at 8:00 a.m. CDT to review fourth quarter 2018 financial results.

• Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets

  7/10/2018

  Knockout Validation of Antibodies Confirms Specificity and Ensures Reproducible Results

• Bio-Techne Expands RNAscope® Assay Services Portfolio to Shorten Development Times and Save Costs

  6/26/2018

  Validated tissue bank and pre-collected immuno-oncology datasets speed up investigative research projects through to clinical development...

• Bio-Techne To Acquire Quad Technologies

  6/7/2018

  The transaction is expected to close in early July and to be financed through available cash on hand.

• Bio-Techne To Present At The William Blair 38th Annual Growth Stock Conference

  6/4/2018

  Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the William Blair 38th Annual Growth Stock Conference.

• Bio-Techne Releases Third Quarter Fiscal 2018 Results

  5/2/2018

  Bio-Techne Corporation reported its financial results for the third quarter ended March 31, 2018.

• Bio-Techne Declares Dividend of $0.32 Per Share

  5/2/2018

  Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2018.

• Bio-Techne Leads the Way in Scientific Support for Autophagy Research

  4/26/2018

  Bio-Techne has a leading role supporting autophagy research.